SCHEDULE 13G/A: BlackRock Discloses 2.9% Passive Stake in MacroGenics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.9% beneficial ownership stake in MacroGenics Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 11 to Schedule 13G regarding its beneficial ownership of MacroGenics Inc. Common Stock.
• As of June 30, 2025, BlackRock, Inc. beneficially owns an aggregate of 1,813,695 shares of MacroGenics Inc. common stock.
• This ownership represents 2.9% of the class of securities.
• BlackRock, Inc. holds sole voting power over 1,808,028 shares and sole dispositive power over 1,813,695 shares.
• No shared voting or dispositive power is reported.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose or effect of changing or influencing the control of MacroGenics Inc.

Sentiment

Score: 5

Explanation: The document is a routine compliance filing by an institutional investor, reporting a passive stake. It contains no information that would significantly alter the perception of the company's financial health or strategic direction, thus indicating a neutral sentiment.

Positives

• BlackRock, Inc., a major institutional investor, maintains a beneficial ownership stake in MacroGenics Inc., indicating continued passive investment interest.

Negatives

• The reported beneficial ownership of 2.9% is below the 5% threshold, which typically reduces the reporting requirements for institutional investors under Rule 13d-1(b).

Future Outlook

The document does not provide any forward-looking statements or guidance regarding MacroGenics Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., detailing its passive investment stake in a biotechnology company, MacroGenics Inc. Such disclosures are common and provide transparency on significant institutional holdings in publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.

Next Steps

• BlackRock, Inc. will continue to comply with SEC reporting requirements for its beneficial ownership in MacroGenics Inc.

Key Dates

Keywords

BlackRock, MacroGenics, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment